Immatics (IMTX) Competitors $10.57 +0.40 (+3.93%) As of 10:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. KYMR, PTGX, CRNX, ZLAB, AKRO, ACAD, AAPG, MIRM, LNTH, and MENSShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), Zai Lab (ZLAB), Akero Therapeutics (AKRO), ACADIA Pharmaceuticals (ACAD), Ascentage Pharma Group International (AAPG), Mirum Pharmaceuticals (MIRM), Lantheus (LNTH), and Jyong Biotech (MENS). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Its Competitors Kymera Therapeutics Protagonist Therapeutics Crinetics Pharmaceuticals Zai Lab Akero Therapeutics ACADIA Pharmaceuticals Ascentage Pharma Group International Mirum Pharmaceuticals Lantheus Jyong Biotech Immatics (NASDAQ:IMTX) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Does the media prefer IMTX or KYMR? In the previous week, Immatics had 1 more articles in the media than Kymera Therapeutics. MarketBeat recorded 9 mentions for Immatics and 8 mentions for Kymera Therapeutics. Immatics' average media sentiment score of 0.54 beat Kymera Therapeutics' score of 0.27 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable earnings and valuation, IMTX or KYMR? Immatics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$168.65M7.62$16.47M-$0.65-16.26Kymera Therapeutics$47.07M91.05-$223.86M-$3.47-17.27 Which has more volatility & risk, IMTX or KYMR? Immatics has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Do analysts recommend IMTX or KYMR? Immatics currently has a consensus target price of $13.67, indicating a potential upside of 29.30%. Kymera Therapeutics has a consensus target price of $61.26, indicating a potential upside of 2.20%. Given Immatics' higher possible upside, equities analysts clearly believe Immatics is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71Kymera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.95 Is IMTX or KYMR more profitable? Immatics has a net margin of -59.29% compared to Kymera Therapeutics' net margin of -616.03%. Immatics' return on equity of -15.60% beat Kymera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-59.29% -15.60% -12.31% Kymera Therapeutics -616.03%-31.60%-27.12% Do institutionals & insiders have more ownership in IMTX or KYMR? 64.4% of Immatics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryImmatics beats Kymera Therapeutics on 11 of the 17 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.28B$3.37B$6.04B$10.53BDividend YieldN/A2.30%5.73%4.80%P/E Ratio-16.2422.7884.5127.54Price / Sales7.62267.44513.90198.23Price / Cash41.3046.9537.5761.53Price / Book2.0610.4912.286.84Net Income$16.47M-$52.58M$3.32B$276.59M7 Day Performance1.93%0.26%-0.30%0.64%1 Month Performance85.44%15.09%9.36%8.73%1 Year Performance11.38%17.56%72.91%35.73% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.6166 of 5 stars$10.57+3.9%$13.67+29.3%+9.4%$1.28B$168.65M-16.24260News CoverageAnalyst UpgradeAnalyst RevisionKYMRKymera Therapeutics1.6228 of 5 stars$57.55-0.6%$61.26+6.5%+26.5%$4.14B$47.07M-16.58170Insider TradePTGXProtagonist Therapeutics1.6846 of 5 stars$64.14-1.1%$68.36+6.6%+66.0%$4.03B$209.18M91.63120Analyst ForecastInsider TradeGap DownCRNXCrinetics Pharmaceuticals3.7476 of 5 stars$41.68+2.0%$74.45+78.6%-17.0%$3.85B$1.04M-10.14210ZLABZai Lab2.7757 of 5 stars$33.31-1.3%$56.35+69.2%+18.9%$3.77B$398.99M-16.331,869News CoveragePositive NewsAKROAkero Therapeutics3.6797 of 5 stars$46.04-0.1%$81.14+76.2%+79.3%$3.69BN/A-23.0230Insider TradeACADACADIA Pharmaceuticals4.5075 of 5 stars$21.59-1.0%$29.12+34.9%+35.8%$3.68B$1.02B16.23510Analyst ForecastAAPGAscentage Pharma Group InternationalN/A$39.86+1.2%N/AN/A$3.67B$134.35M0.00600News CoverageGap DownMIRMMirum Pharmaceuticals3.3023 of 5 stars$72.53-0.6%$76.50+5.5%+84.3%$3.66B$336.89M-59.94140LNTHLantheus4.5678 of 5 stars$52.70-2.1%$85.50+62.2%-50.3%$3.66B$1.53B14.02700Analyst RevisionMENSJyong BiotechN/A$52.01+8.4%N/AN/A$3.65BN/A0.0031Gap Down Related Companies and Tools Related Companies Kymera Therapeutics Competitors Protagonist Therapeutics Competitors Crinetics Pharmaceuticals Competitors Zai Lab Competitors Akero Therapeutics Competitors ACADIA Pharmaceuticals Competitors Ascentage Pharma Group International Competitors Mirum Pharmaceuticals Competitors Lantheus Competitors Jyong Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
